Roche announces that it has been awarded WHO prequalification designations for Human Papillomavirus (HPV) testing for use on the cobas 5800 system and for self-collected samples on the cobas 5800, 6800 and 8800 systems.

This pre-qualification enables low- and middle-income countries to use these screening solutions, including self-collection, in their national cervical cancer elimination programs, significantly improving access.

Every year, more than 600,000 women worldwide are diagnosed with cervical cancer, and more than 340,000 die from this preventable disease caused by HPV infection", the Swiss healthcare group points out.

Copyright (c) 2024 CercleFinance.com. All rights reserved.